Immunosuppressive Treatment of Primary Sclerosing Cholangitis

1996 ◽  
Vol 6 (6) ◽  
pp. 479-488
Author(s):  
Nicola Maria ◽  
Alessandra Colantoni ◽  
David H. Thiel
Keyword(s):  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Immunosuppressive Treatment

scholarly journals Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0140525 ◽  
Author(s):  
Kornelius Schulze ◽  
Tobias J. Weismüller ◽  
Michael Bubenheim ◽  
Peter Huebener ◽  
Roman Zenouzi ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Immunosuppressive Treatment

scholarly journals Primary Sclerosing Cholangitis

2000 ◽  
Vol 14 (4) ◽  
pp. 311-315 ◽  
Author(s):  
A Stiehl ◽  
C Benz ◽  
P Sauer
Keyword(s):  
Ulcerative Colitis ◽  
Liver Transplantation ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Immunosuppressive Treatment ◽  
Prolonged Treatment ◽  
Cholestatic Liver Disease ◽  
Biliary Cirrhosis ◽  
Stage Disease ◽  
End Stage

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by fibrosing inflammation and obliteration of intra- and/or extrahepatic bile ducts. The disease is one of the most common cholestatic diseases in adults and is diagnosed with increasing frequency. It is very often associated with ulcerative colitis. Patients with PSC have an increased incidence of bile duct carcinomas, and those with ulcerative colitis also have an increased incidence of colonic carcinomas. In end-stage disease, liver transplantation is the treatment of choice. Immunosuppressive treatment has little effect. Ursodeoxycholic acid (UDCA), which has been shown to improve liver histology and survival in patients with primary biliary cirrhosis, has a beneficial effect in PSC, provided that patients who develop major duct stenoses are treated endoscopically. The aim is to treat patients as early as possible to prevent progression to the advanced stages of the disease. During treatment with UDCA, stenoses of major ducts may develop, and early endoscopic dilation is highly effective. Because UDCA treatment improves but does not cure cholestatic liver diseases, permanent treatment seems to be necessary. Such prolonged treatment with UDCA may be recommended because, until now, no side effects have been reported. In patients with end-stage disease, UDCA is not effective and liver transplantation is indicated.

New autoantibodies in primary sclerosing cholangitis: reactivity with distinct immunodominant epitopes of sulfite oxidase

2010 ◽  
Vol 48 (01) ◽  
Author(s):  
BE Preuß ◽  
C Berg ◽  
F Altenberend ◽  
M Gregor ◽  
S Stevanovic ◽  
...  
Keyword(s):  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Sulfite Oxidase ◽  
Immunodominant Epitopes

Bile proteomic profiles differentiates cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis

2011 ◽  
Vol 24 (01) ◽  
Author(s):  
T Lankisch ◽  
J Metzger ◽  
A Negm ◽  
K Voßkuhl ◽  
E Schiffer ◽  
...  
Keyword(s):  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis

Dysplasia associated lesion or mass (DALM) in a patient with ulcerative colitis complicated with primary sclerosing cholangitis

2012 ◽  
Vol 50 (05) ◽  
Author(s):  
Á Vincze ◽  
I Hegedűs ◽  
Ö Horváth ◽  
B Bogner
Keyword(s):  
Ulcerative Colitis ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis

Hepatocellular carcinoma does not significantly contribute to the risk of hepatobiliary malignancy in cirrhotic patients with primary sclerosing cholangitis

2013 ◽  
Vol 51 (01) ◽  
Author(s):  
R Zenouzi ◽  
TJ Weismüller ◽  
P Hübener ◽  
K Schulze ◽  
M Bubenheim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Cirrhotic Patients

Anti-neutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis

2013 ◽  
Vol 51 (01) ◽  
Author(s):  
H Lenzen ◽  
TJ Weismüller ◽  
AA Negm ◽  
J Wlecke ◽  
CP Strassburg ◽  
...  
Keyword(s):  
Disease Activity ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis

Disease specific alterations of the bile-duct derived biliary proteome in primary sclerosing cholangitis

2013 ◽  
Vol 51 (08) ◽  
Author(s):  
C Rupp ◽  
K Bode ◽  
Y Schäfer ◽  
KH Weiss ◽  
P Schirmacher ◽  
...  
Keyword(s):  
Bile Duct ◽  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Disease Specific

The Role of IFNγ in the Immune Pathogenesis of Primary Sclerosing Cholangitis

2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
G Ravichandran ◽  
T Krech ◽  
G Tiegs ◽  
R Barikbin
Keyword(s):  
Primary Sclerosing Cholangitis ◽  
Sclerosing Cholangitis ◽  
Immune Pathogenesis
Sign in / Sign up

Export Citation Format

Share Document